CA2967336C - Cancer immunotherapy using virus particles - Google Patents

Cancer immunotherapy using virus particles Download PDF

Info

Publication number
CA2967336C
CA2967336C CA2967336A CA2967336A CA2967336C CA 2967336 C CA2967336 C CA 2967336C CA 2967336 A CA2967336 A CA 2967336A CA 2967336 A CA2967336 A CA 2967336A CA 2967336 C CA2967336 C CA 2967336C
Authority
CA
Canada
Prior art keywords
cancer
tumor
virus
ecpmv
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2967336A
Other languages
English (en)
French (fr)
Other versions
CA2967336A1 (en
Inventor
Nicole F. Steinmetz
Amy M. WEN
Steven Fiering
Patrick H. LIZOTTE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dartmouth College
Case Western Reserve University
Original Assignee
Dartmouth College
Case Western Reserve University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dartmouth College, Case Western Reserve University filed Critical Dartmouth College
Publication of CA2967336A1 publication Critical patent/CA2967336A1/en
Application granted granted Critical
Publication of CA2967336C publication Critical patent/CA2967336C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32071—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2967336A 2014-11-07 2015-11-09 Cancer immunotherapy using virus particles Active CA2967336C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462076543P 2014-11-07 2014-11-07
US62/076,543 2014-11-07
US201562107617P 2015-01-26 2015-01-26
US62/107,617 2015-01-26
US201562159389P 2015-05-11 2015-05-11
US62/159,389 2015-05-11
PCT/US2015/059675 WO2016073972A1 (en) 2014-11-07 2015-11-09 Cancer immunotherapy using virus particles

Publications (2)

Publication Number Publication Date
CA2967336A1 CA2967336A1 (en) 2016-05-12
CA2967336C true CA2967336C (en) 2023-09-26

Family

ID=55909946

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2967336A Active CA2967336C (en) 2014-11-07 2015-11-09 Cancer immunotherapy using virus particles

Country Status (7)

Country Link
US (4) US10639363B2 (enExample)
EP (2) EP3957644B1 (enExample)
JP (1) JP6731405B2 (enExample)
CN (1) CN107001428B (enExample)
AU (1) AU2015342790B2 (enExample)
CA (1) CA2967336C (enExample)
WO (2) WO2016073972A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10086095B2 (en) 2012-10-09 2018-10-02 Case Western Reserve University Rod-shaped plant virus nanoparticles as imaging agent platforms
US11193111B2 (en) 2013-01-17 2021-12-07 Case Western Reserve University Viral nanoparticle multimers
US11998594B2 (en) 2014-04-02 2024-06-04 Case Western Reserve University Anti-cancer plant virus particles linked to HER2 antigens
US9925281B2 (en) 2014-08-05 2018-03-27 Case Western Reserve University Coated plant virus imaging agents
US12465624B2 (en) 2018-05-08 2025-11-11 Case Western Reserve University Cancer immunotherapy using virus particles and immune checkpoint therapy
JP6731405B2 (ja) * 2014-11-07 2020-07-29 ケース ウエスタン リザーブ ユニバーシティ ウイルス粒子を用いた癌免疫療法
US11617787B2 (en) 2014-11-07 2023-04-04 Case Western Reserve University Cancer immunotherapy using virus particles
US10624975B2 (en) 2015-06-29 2020-04-21 Case Western Reserve University Anticancer drug-containing plant virus particles
US10478510B2 (en) 2015-07-16 2019-11-19 Case Western Resrve University Plant virus particles for delivery of antimitotic agents
US11433123B2 (en) 2016-07-21 2022-09-06 Case Western Reserve University Sustained release cowpea mosaic virus or virus-like particle therapeutic constructs for the treatment of cancer
AU2017354004C1 (en) 2016-11-03 2023-08-31 Case Western Reserve University Melt processed viral nanoparticle constructs
US12433840B2 (en) 2016-11-03 2025-10-07 Case Western Reserve University Melt processed viral nanoparticle constructs
US11590183B2 (en) 2017-03-10 2023-02-28 Case Western Reserve University Cancer immunotherapy using virus particles
US11672840B2 (en) 2017-05-17 2023-06-13 Case Western Reserve University Anticancer trail-targeted plant virus particles
WO2019084555A1 (en) 2017-10-27 2019-05-02 Case Western Reserve University TYMOVIRUS VIRUSES AND VIRAL TYPE PARTICLES USEFUL AS NANOVECTORS FOR IMAGING AND THERAPEUTIC AGENTS
WO2019173487A1 (en) * 2018-03-06 2019-09-12 University Of Louisville Research Foundation, Inc. Methods for treatment of cancer and enhancement of nanoparticle accumulation in tissues
JP7641005B2 (ja) * 2018-12-27 2025-03-06 ヴェリミューン インコーポレイテッド コンジュゲート型ウイルス様粒子および抗腫瘍免疫リダイレクタとしてのその使用
US20220145316A1 (en) * 2019-03-01 2022-05-12 The Regents Of The University Of California Cancer immunotherapy
US11390853B2 (en) 2019-04-26 2022-07-19 Case Western Reserve University Freeze dried viral nanoparticle constructs
US11896676B2 (en) 2019-08-07 2024-02-13 Case Western Reserve University Targeting cancer cells and tissue using filamentous plant virus particles
CN110859861A (zh) * 2019-12-04 2020-03-06 武汉工程大学 植物病原微生物杀灭癌细胞或艾滋病病毒的用途
US11529430B2 (en) 2019-12-20 2022-12-20 Case Western Reserve University Polydopamine decorated tobacco mosaic theranostic virus nanoparticles
US12203073B2 (en) 2019-12-20 2025-01-21 Case Western Reserve University Plant viral RNA delivery nanoparticles and uses thereof
US20240066108A1 (en) * 2021-01-08 2024-02-29 The Regents Of The University Of California Ovarian cancer vaccine
JP2025504361A (ja) * 2022-01-19 2025-02-12 ウニベルズィテート ベルン ウイルス様粒子と微結晶性チロシンとの組成物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004606A (en) 1986-09-24 1991-04-02 Hybritech Incorporated Non-covalent antibody-anthracycline immunocomplexes
GB9921337D0 (en) * 1999-09-09 1999-11-10 Axis Genetics Plc Modified plant viruses
GB9924351D0 (en) * 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
TWI438010B (zh) 2002-05-02 2014-05-21 Wyeth Corp 卡奇黴素（ｃａｌｉｃｈｅａｍｉｃｉｎ）衍生物-載體共軛物
CA2435632A1 (en) * 2003-07-21 2005-01-21 Warren Hugh Finlay Formulation of powder containing nanoparticles for aerosol delivery to the lung
RU2006146605A (ru) 2004-06-02 2008-07-20 Цитос Биотехнологи Аг (Ch) Медицинские применения конъюгатов-носителей tnf-пептидов из организма кроме человека
WO2008048288A2 (en) 2005-11-09 2008-04-24 Montana State University Novel nanoparticles and use thereof
AU2006351933A1 (en) * 2005-12-02 2008-07-17 Dow Global Technologies Inc. Novel plant virus particles and methods of inactivation thereof
US7771339B2 (en) * 2006-05-31 2010-08-10 Ab Mimator Method and system for radiotherapy treatment
US20100183504A1 (en) 2007-06-14 2010-07-22 Fanqing Frank Chen Multimodal imaging probes for in vivo targeted and non-targeted imaging and therapeutics
WO2016149264A1 (en) 2015-03-18 2016-09-22 The Johns Hopkins University Compositions and methods for sensitizing cells to trail-induced apoptosis
EP2327764B1 (en) * 2009-11-30 2011-12-28 United Cancer Research Institute New clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer
US20130236491A1 (en) 2010-12-09 2013-09-12 Iosif Grigorievich Atabekov Spherical nano and microparticles derived from plant viruses for the display of foreign proteins or epitopes
WO2013018155A1 (ja) 2011-07-29 2013-02-07 株式会社ユーテック 強誘電体膜およびその製造方法
WO2013158620A1 (en) 2012-04-16 2013-10-24 North Carolina State University Nanotechnology system for agricultural applications
CN109876139A (zh) 2012-04-24 2019-06-14 俄亥俄州国家创新基金会 用于治疗和预防猪繁殖与呼吸综合征的组合物和方法
US10232057B2 (en) 2012-05-31 2019-03-19 Case Western Reserve University Targeting cancer cells and tissue using filamentous plant virus particles
US10086095B2 (en) 2012-10-09 2018-10-02 Case Western Reserve University Rod-shaped plant virus nanoparticles as imaging agent platforms
US20160228541A1 (en) * 2013-09-19 2016-08-11 Alain Lamarre Papaya mosaic virus and virus-like particles in cancer therapy
WO2015188110A1 (en) 2014-06-05 2015-12-10 The Johns Hopkins University Reversible pegylation for screeing of therapeutic proteins in vivo
EP3174976B1 (en) 2014-08-01 2020-10-28 GPB Scientific, Inc. Methods and systems for processing particles
US9925281B2 (en) 2014-08-05 2018-03-27 Case Western Reserve University Coated plant virus imaging agents
JP6731405B2 (ja) * 2014-11-07 2020-07-29 ケース ウエスタン リザーブ ユニバーシティ ウイルス粒子を用いた癌免疫療法
US10624975B2 (en) * 2015-06-29 2020-04-21 Case Western Reserve University Anticancer drug-containing plant virus particles
US10478510B2 (en) 2015-07-16 2019-11-19 Case Western Resrve University Plant virus particles for delivery of antimitotic agents
US11672840B2 (en) 2017-05-17 2023-06-13 Case Western Reserve University Anticancer trail-targeted plant virus particles

Also Published As

Publication number Publication date
EP3215520A1 (en) 2017-09-13
JP6731405B2 (ja) 2020-07-29
AU2015342790A1 (en) 2017-06-08
US20230024508A1 (en) 2023-01-26
US20180133304A1 (en) 2018-05-17
JP2017533920A (ja) 2017-11-16
EP3957644B1 (en) 2024-08-07
EP3957644A1 (en) 2022-02-23
US11260121B2 (en) 2022-03-01
CN107001428A (zh) 2017-08-01
EP3215520B1 (en) 2022-01-05
US10639363B2 (en) 2020-05-05
CA2967336A1 (en) 2016-05-12
AU2015342790B2 (en) 2019-10-03
US11730803B2 (en) 2023-08-22
US20240024452A1 (en) 2024-01-25
US12350326B2 (en) 2025-07-08
WO2018208828A1 (en) 2018-11-15
WO2016073972A1 (en) 2016-05-12
US20210052717A1 (en) 2021-02-25
EP3215520A4 (en) 2018-06-06
CN107001428B (zh) 2023-01-10

Similar Documents

Publication Publication Date Title
US12350326B2 (en) Cancer immunotherapy using virus particles
Lizotte et al. In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer
US10905774B2 (en) Nanocage and use thereof
Zheng et al. Targeted cancer therapy using engineered Salmonella typhimurium
JP6662787B2 (ja) 癌免疫療法のための新規ｍｓｌｎ標的化ｄｎａワクチン
Siebert et al. Tuftsin-properties and analogs
JP7487892B2 (ja) 医薬ベシクル製剤を調製するための方法、ならびに関連する製品および使用
US12070478B2 (en) Cancer immunotherapy using virus particles
EP3592343B1 (en) Cancer immunotherapy using virus particles
HK40068065A (en) Cancer immunotherapy using virus particles
CN114632149A (zh) 溶瘤病毒和免疫调节剂在协同抑制晚期肝癌中的应用
HK40068065B (en) Cancer immunotherapy using virus particles
US11590183B2 (en) Cancer immunotherapy using virus particles
Zhu et al. Intestinal probiotic-based nanoparticles for cytotoxic siRNA delivery in immunotherapy against cancer
TWI359030B (en) Treatment of cellular proliferative disorders
Khan et al. Recent Advances in Bacterium‐Based Therapeutic Modalities for Melanoma Treatment
Gautam et al. Role of macrophage in tumor microenvironment: prospect in cancer immunotherapy
JP2009091348A (ja) がんの治療方法
JP2025537780A (ja) 癌の治療用免疫増強サルモネラ菌株およびその用途
KR20240110161A (ko) 열 반응성 하이브리드 나노입자가 접합된 rmPD-1 단백질 복합체 및 이의 용도
CN118576624A (zh) 一种自溶沙门氏菌-纳米胶囊输送系统、免疫刺激水凝胶及其应用
Sawaya 48 Novel Therapies for Brain Tumors
Mok et al. 454. Evaluation of Polyethylene Glycol (PEG) Modification of Adenoviral Vectors To Reduce Innate Immune Response and Increase Vector Persistence
Morrison et al. 456. A Comparison of Adenoviral-Mediated Gene Transfer in Human and Mouse Dendritic Cells

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181108

EEER Examination request

Effective date: 20181108

EEER Examination request

Effective date: 20181108

EEER Examination request

Effective date: 20181108

EEER Examination request

Effective date: 20181108

EEER Examination request

Effective date: 20181108

EEER Examination request

Effective date: 20181108

EEER Examination request

Effective date: 20181108